Matt Luther, MD MSCI
LightNews LightNews
banner
drjmluther.bsky.social
Matt Luther, MD MSCI
@drjmluther.bsky.social
930 followers 580 following 130 posts
Nephrologist, Hypertension specialist, Physician-scientist.
Posts Replies Media Videos
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
Chronotherapy in the news again?

@medscape.com discusses the story so far with the new ONAM study www.medscape.com/viewarticle/...

@drlabos.bsky.social feat Scott Garrison and moi

#Hypertension
Are BP Meds More Effective if Taken at Night?
The OMAN trial reignited the debate on whether it makes a difference clinically if antihypertensives are taken in the morning or the evening. Cardiologist Chris Labos reviews the evidence.
www.medscape.com
October 29, 2025 at 9:57 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
Hypertension Secrets has been translated into multiple languages, including Lithuanian!

Get your copy here: shop.elsevier.com/books/hypert...

@edgarvlermamd.bsky.social @drjmluther.bsky.social
Lithuanian copy of Hypertension Secrets
September 17, 2025 at 4:07 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
The CPC from last @ahascience.bsky.social #HypertensionSessions now published in @ahajournals.bsky.social

www.ahajournals.org/doi/10.1161/...

thanks to @drjmluther.bsky.social and all the education editors for the invite

We hope it makes for an educational read!
August 20, 2025 at 6:09 PM
Reposted by Matt Luther, MD MSCI
jordybc.bsky.social
New 2025 AHA/ACC Hypertension Guideline dropped!

www.jacc.org/doi/10.1016/...

#hypertension #medsky #nephsky
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College o...
www.jacc.org
August 14, 2025 at 6:06 PM
Reposted by Matt Luther, MD MSCI
laskerfdn.bsky.social
#LaskerLaureate Rustom Jal Vakil was born #OTD in 1911. He won a #LaskerAward in 1957 for his studies on the use of reserpine in the treatment of #hypertension. ow.ly/bFTR50FunRI 🧪
Treatment of hypertension - Lasker Foundation
Explore All 1957 Winners & Awards > Rustom Jal VakilKing Edward VII Memorial Hospital, Bombay For studies on the use of reserpine in the treatment of hypertension. The story of Rauwolfia…
ow.ly
July 17, 2025 at 2:06 PM
Reposted by Matt Luther, MD MSCI
drwanpen.bsky.social
New PA Endo guideline is also out by experts @anandvaidya17.bsky.social #Cardiosky @hswapnil.medsky.social doi.org/10.1210/clin...
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
AbstractBackground. Primary aldosteronism (PA), a primary adrenal disorder leading to excessive aldosterone production by one or both adrenal glands, is a
doi.org
July 14, 2025 at 6:56 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
The first #ERA25 simultaneous pub

CONFIDENCE trial of empagliflozin + finerenone in N = 579

Greater reduction in ACR and BP
Note the impressive GFR dip

www.nejm.org/doi/full/10....
Urinary Albumin-to-Creatinine Ratio, Serum Potassium Level, Estimated Glomerular Filtration Rate, and Systolic Blood Pressure over Time.
June 5, 2025 at 9:54 AM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
Plenary at @hypertensioncanada.bsky.social with @drjmluther.bsky.social on new drugs

He starts of with the really old drugs!

#CHC25
old drugs in HT
May 29, 2025 at 2:11 PM
Reposted by Matt Luther, MD MSCI
jordybc.bsky.social
Phase 2 trial of the new antihypertensive agent, ultra-long-acting (q6 month), subq, small interfering RNA against angiotensinogen (Zilebesiran), hit JAMA!

h/t @drjmluther.bsky.social

jamanetwork.com/journals/jam...

1/
Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension
This randomized clinical trial examines the efficacy and safety of zilebesiran vs placebo when added to a standard antihypertensive medication in adult patients with uncontrolled hypertension.
jamanetwork.com
May 28, 2025 at 8:09 PM
drjmluther.bsky.social
Matt Luther, Nephrologist/HTN specialist
COI: Mineralys consulting
#NephJC
May 28, 2025 at 1:08 AM
Reposted by Matt Luther, MD MSCI
mineralystx.com
Today we presented detailed results from our pivotal Ph3 Launch-HTN trial at #ESH2025, reinforcing the promise of lorundrostat as a new treatment approach for aldosterone driven #hypertension.

Read our press release to learn more: ir.mineralystx.com/news-events/...

$MLYS #bloodpressure
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
May 24, 2025 at 12:08 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
There you have it: BEDMED published in @jama.com

jamanetwork.com/journals/jam...

h/t @drjmluther.bsky.social

No difference in bedtime versus morning BP meds - as expected

#NephSky #Hypertension
1/
Figure of survival curve showing no difference
May 12, 2025 at 9:46 PM
Reposted by Matt Luther, MD MSCI
jordybc.bsky.social
Aaand it’s official, we have a new antihypertensive class!!!! 🎉🍾🎊

I like this RCT design in particular because it was open to both uncontrolled not-yet-resistant AND resistant hypertensive patients, opening to door to prescribe it as an earlier line agent

www.nejm.org/doi/full/10....
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
www.nejm.org
April 23, 2025 at 10:38 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
The ASIs have arrived

www.nejm.org/doi/full/10....

Aldosterone synthase inhibitors - first one to finish the phase 3 line

#Lorundrostat #Hypertension
Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension | NEJM
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. In this mult...
www.nejm.org
April 23, 2025 at 10:01 PM
drjmluther.bsky.social
How often have you seen Ferric Carboxymaltose cause hypophosphatemia? @kidneyboy.bsky.social @hswapnil.medsky.social @askrenal.bsky.social #askrenal

pubmed.ncbi.nlm.nih.gov/39659775/
In-depth clinical characterization of intravenous iron infusion-induced hypophosphatemic osteomalacia and its resolution - PubMed
Iron deficiency anemia is treated by iron supplementation. Increasing evidence has shown that the carbohydrate components in iron infusions can cause hypophosphatemia and subsequent osteomalacia due t...
pubmed.ncbi.nlm.nih.gov
April 21, 2025 at 9:23 PM
Reposted by Matt Luther, MD MSCI
ajkd.bsky.social
Treatment Effect Heterogeneity in Acute Kidney Injury Incidence Following Intravenous Antihypertensive Administration for Severe Blood Pressure Elevation During Hospitalization

bit.ly/3CEO9n1 #OpenAccess
April 12, 2025 at 10:01 PM
Reposted by Matt Luther, MD MSCI
weddellite.bsky.social
We showed a dramatic difference (dramatic for a small sample size!) in the effect of CTD vs HCTZ on urine calcium. That's my preference for stone prevention. RCT with stone outcome needed. pubmed.ncbi.nlm.nih.gov/40194294/
Effect of Chlorthalidone and Hydrochlorothiazide on Twelve-Hour versus Twenty-Four Hour Urinary Calcium Excretion - PubMed
We conclude that the long-acting and more effective CTD is a preferable agent for stone prevention. Time of administration does not appear to be important, although morning administration may more eff...
pubmed.ncbi.nlm.nih.gov
April 11, 2025 at 11:39 AM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
Retatrutide (GLP, GIP, Glucagon receptor agonist) and albuminuria and GFR changes from phase 2 trial now in @kireports.bsky.social

Two Ph2 trials, one in T2DM and another in Obesity with about N ~ 300 each

uACR reduced in both RCTs (A, B)
Much more pronounced when baseline > 30 mg/g (C, D)
1/
Figure 1 Changes in UACR with retatrutide versus placebo. The figure shows the percent change from baseline in UACR. Data are least-squares means with error bars showing standard errors derived from the MMRM of the efficacy analysis set. Percent change from baseline in UACR over time from the MMRM analysis for all participants in the (A) T2D study and (B) obesity efficacy population and among participants with baseline UACR of ≥30 mg/g in the (C) T2D and (D) obesity trials. Abbreviations: MMRM= mixed model repeated measures. RETA=retatrutide. SE=standard error. T2D=type 2 diabetes. UACR=urine albumin-to-creatinine ratio.
April 3, 2025 at 9:30 PM
Reposted by Matt Luther, MD MSCI
rnflex.bsky.social
Wait it's wilder. Always check the appendix. They broke down BP reductions by >140 or <140 systolic & >90 or <90 diastolic.

Those with HTN saw average reductions of 30mmhg systolic & 15mmHg diastolic for obese patients & 20/10 for diabetics.

🤯🤯
Also 41% of pts stopped one BP med on 12mg dose
Supplementary Figure S1. Changes from baseline in systolic BP among subgroups of participants with baseline systolic BP of <140 versus 2140 mm Hg for the (A,B) T2D study population and the (C,D) obesity study efficacy population. Reductions up to 30mmhg were seen in the group with BP greater than 140 Supplementary Figure S2. Changes from baseline in diastolic BP among subgroups of participants with baseline diastolic BP of <90 versus 290 mm Hg for the (A,B) T2D study efficacy population and the (C,D) obesity study efficacy population. Reductions in diastolic BP up to 15mmHg were seen in patients with a diastolic >90
April 4, 2025 at 10:33 AM
Reposted by Matt Luther, MD MSCI
mjskay.com
behold the CONNECTED SPLATTERPIE

kneel before my works, ye mighty, and despair
A connected splatterpie: a connected scatterplot where the points are pie charts and the connecting lines are splines. Shows three time series, all increasing from 2013 to 2024: (1) How awesome are spline smooths (out of 10); (2) How many charts are dual-axis charts (going up to ~ 2.0M); (3) % of line charts with splines (going up to ~ 60%).
March 30, 2025 at 9:00 PM
Reposted by Matt Luther, MD MSCI
heatherlgornik.bsky.social
Great pearls by @jbrianbyrd.bsky.social in evaluating pts for RDN at #ACC25: 1. confirm uncontrolled HTN with out of office measure (Amb BP monitor); 2. trial spironolactone 1st; 3.
shared decision making key - care team should include HTN specialists beyond those performing the procedure #cardiosky
March 30, 2025 at 5:08 PM
Reposted by Matt Luther, MD MSCI
hswapnil.medsky.social
From @spjuraschek.bsky.social et al in the @bmj.com

www.bmj.com/content/388/...

Orthostatic #hypertension seems bad, but lowering BP intensively also lowers this

#NephSky
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysis
Objective To determine the effects of intensive blood pressure treatment on orthostatic hypertension. Design Systematic review and individual participant data meta-analysis. Data sources MEDLINE, Em...
www.bmj.com
March 26, 2025 at 12:09 AM
Reposted by Matt Luther, MD MSCI
edgarvlermamd.bsky.social
Chloride depletion alkalosis (as opposed to what was previously called 'contraction alkalosis') #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/22223876/
March 24, 2025 at 1:09 AM
Reposted by Matt Luther, MD MSCI
amglazer.bsky.social
🧵 I’m excited to share our latest preprint! We studied 252 SCN5A variants found in patients with Brugada Syndrome by automated patch clamp. [1/7]
March 20, 2025 at 1:53 AM
Reposted by Matt Luther, MD MSCI
genetickidneydoc.bsky.social
Our #rFSGS biobank is growing and we welcome patients from all over the world! Please reach out to us if you are a patient or a physician caring for one. We are creating a resource for everyone to use with the goal of resolving this disease and find new cures.
#KidneyMonth2025 #RareDisease #genetics
rfsgsinitiative.bsky.social rFSGS Initiative @rfsgsinitiative.bsky.social · Mar 17
Building a biobank is key to finding new treatments for Recurrent Focal Segmental Glomerulosclerosis. If you or someone you know has #rFSGS and you want to learn how you can help by providing a biosample, email mb5150@cumc.columbia.edu.

#KidneyMonth #KidneyTransplant #nephsky #medsky #skyneph
March 18, 2025 at 5:33 PM